JP6918819B2 - オルトミクソウイルス感染の処置に有用な三環式化合物 - Google Patents
オルトミクソウイルス感染の処置に有用な三環式化合物 Download PDFInfo
- Publication number
- JP6918819B2 JP6918819B2 JP2018547307A JP2018547307A JP6918819B2 JP 6918819 B2 JP6918819 B2 JP 6918819B2 JP 2018547307 A JP2018547307 A JP 2018547307A JP 2018547307 A JP2018547307 A JP 2018547307A JP 6918819 B2 JP6918819 B2 JP 6918819B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- pharmaceutically acceptable
- ring
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AJVXSKCJVFQMBZ-RUZDIDTESA-N C=[Br]c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 Chemical compound C=[Br]c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 AJVXSKCJVFQMBZ-RUZDIDTESA-N 0.000 description 1
- PHZVOXJWCROCGO-LJQANCHMSA-N CC(OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O)=O Chemical compound CC(OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O)=O PHZVOXJWCROCGO-LJQANCHMSA-N 0.000 description 1
- BKJAAHYPKYYXDR-OTOKDRCRSA-N CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)O Chemical compound CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)O BKJAAHYPKYYXDR-OTOKDRCRSA-N 0.000 description 1
- BZNXSEXRGLMSIC-RZIURPKCSA-N CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)O Chemical compound CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)O BZNXSEXRGLMSIC-RZIURPKCSA-N 0.000 description 1
- SEUGYZHGQXZGJU-UHFFFAOYSA-N CCC([n]1c2ncc1)N(C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O Chemical compound CCC([n]1c2ncc1)N(C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O SEUGYZHGQXZGJU-UHFFFAOYSA-N 0.000 description 1
- ZTWDNXGMOKHLGO-HXUWFJFHSA-N CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)=O Chemical compound CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)=O ZTWDNXGMOKHLGO-HXUWFJFHSA-N 0.000 description 1
- JSZATNWYUXBKGW-HHHXNRCGSA-N CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)=O Chemical compound CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)=O JSZATNWYUXBKGW-HHHXNRCGSA-N 0.000 description 1
- CYVDNIFUERLGCM-HXUWFJFHSA-N Cc1c(C)nc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O Chemical compound Cc1c(C)nc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O CYVDNIFUERLGCM-HXUWFJFHSA-N 0.000 description 1
- FEVGXTBZUUITCJ-AREMUKBSSA-N O=Cc1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 Chemical compound O=Cc1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 FEVGXTBZUUITCJ-AREMUKBSSA-N 0.000 description 1
- MHWFNXWCPQNGRQ-XMMPIXPASA-N OC1=C(c2ncc(-c3ccccc3)[n]2C[C@@H]2C(c3ccccc3)c3ccccc3)N2C=CC1=O Chemical compound OC1=C(c2ncc(-c3ccccc3)[n]2C[C@@H]2C(c3ccccc3)c3ccccc3)N2C=CC1=O MHWFNXWCPQNGRQ-XMMPIXPASA-N 0.000 description 1
- AWIJSMFVNDAWRA-UHFFFAOYSA-N OC1=C(c2ncc[n]2CC2C(c3cccc(Cl)c3)c3cc(Cl)ccc3)N2N=CC1=O Chemical compound OC1=C(c2ncc[n]2CC2C(c3cccc(Cl)c3)c3cc(Cl)ccc3)N2N=CC1=O AWIJSMFVNDAWRA-UHFFFAOYSA-N 0.000 description 1
- SHISIZVWEDLGHH-QGZVFWFLSA-N OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O Chemical compound OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O SHISIZVWEDLGHH-QGZVFWFLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305392P | 2016-03-08 | 2016-03-08 | |
| US62/305,392 | 2016-03-08 | ||
| PCT/IB2017/051338 WO2017153919A1 (en) | 2016-03-08 | 2017-03-07 | Tricyclic compounds useful to treat orthomyxovirus infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512485A JP2019512485A (ja) | 2019-05-16 |
| JP2019512485A5 JP2019512485A5 (https=) | 2020-05-28 |
| JP6918819B2 true JP6918819B2 (ja) | 2021-08-11 |
Family
ID=58347733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547307A Active JP6918819B2 (ja) | 2016-03-08 | 2017-03-07 | オルトミクソウイルス感染の処置に有用な三環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858366B2 (https=) |
| EP (1) | EP3426656B1 (https=) |
| JP (1) | JP6918819B2 (https=) |
| CN (1) | CN108699059B (https=) |
| ES (1) | ES2881776T3 (https=) |
| WO (1) | WO2017153919A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201708721XA (en) | 2015-04-28 | 2017-11-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and prodrug thereof |
| SG11201804348SA (en) | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| ES2881776T3 (es) * | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| KR20190018469A (ko) | 2016-08-10 | 2019-02-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CN118878544A (zh) * | 2018-02-28 | 2024-11-01 | 诺华股份有限公司 | 作为正粘病毒复制抑制剂用于治疗流感的化合物 |
| JP2022500466A (ja) | 2018-09-21 | 2022-01-04 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| CN111410661B (zh) * | 2019-01-04 | 2023-05-05 | 周雨恬 | 帽依赖性内切核酸酶抑制剂及其用途 |
| CN109912624B (zh) * | 2019-04-11 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种巴洛沙韦酯关键母核中间体的合成方法 |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| ES2572030T3 (es) * | 2001-08-10 | 2017-07-19 | Shionogi & Co., Ltd. | Agente antiviral |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US20070161639A1 (en) | 2004-03-09 | 2007-07-12 | Philip Jones | Hiv integrase inhibitors |
| FR2901795A1 (fr) * | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| CN102203100B (zh) | 2008-10-31 | 2014-08-27 | 盐野义制药株式会社 | 具有邻苯二酚基团的头孢菌素 |
| EP2412708A4 (en) * | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8927710B2 (en) | 2009-06-15 | 2015-01-06 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| TW201201813A (en) * | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| DK2620436T3 (en) | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| US9328075B2 (en) * | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| RU2014113230A (ru) | 2011-10-12 | 2015-11-20 | Шионоги Энд Ко., Лтд. | Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы |
| JP6089108B2 (ja) | 2012-09-20 | 2017-03-01 | セルトリオン， インク． | ドラスタチン１０誘導体、その製造方法およびそれを含む抗癌剤組成物 |
| CA2894642A1 (en) * | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| AU2014308991B2 (en) | 2013-08-21 | 2019-02-14 | Janssen Biopharma, Inc. | Antiviral compounds |
| US10098913B2 (en) | 2013-09-11 | 2018-10-16 | University Of Southern California | Composition of stem cells having highly expressed FAS ligand |
| SI3030549T1 (sl) | 2013-09-12 | 2019-08-30 | Janssen Biopharma, Inc. | Spojine piridazinona in njihove uporabe |
| MX377396B (es) | 2013-09-12 | 2025-03-10 | Janssen Biopharma Inc | Compuestos de azapiridona y usos de los mismos. |
| CN107074880A (zh) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 |
| US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2881776T3 (es) * | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| KR20190018469A (ko) | 2016-08-10 | 2019-02-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| US11247993B2 (en) | 2018-01-17 | 2022-02-15 | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. | Pyridone derivative, composition and use as antiviral drug thereof |
| CN118878544A (zh) | 2018-02-28 | 2024-11-01 | 诺华股份有限公司 | 作为正粘病毒复制抑制剂用于治疗流感的化合物 |
-
2017
- 2017-03-07 ES ES17711349T patent/ES2881776T3/es active Active
- 2017-03-07 JP JP2018547307A patent/JP6918819B2/ja active Active
- 2017-03-07 US US16/083,089 patent/US10858366B2/en active Active
- 2017-03-07 EP EP17711349.5A patent/EP3426656B1/en active Active
- 2017-03-07 CN CN201780015673.6A patent/CN108699059B/zh active Active
- 2017-03-07 WO PCT/IB2017/051338 patent/WO2017153919A1/en not_active Ceased
-
2020
- 2020-07-20 US US16/933,000 patent/US11453677B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2881776T3 (es) | 2021-11-30 |
| WO2017153919A1 (en) | 2017-09-14 |
| US10858366B2 (en) | 2020-12-08 |
| JP2019512485A (ja) | 2019-05-16 |
| CN108699059B (zh) | 2021-06-18 |
| CN108699059A (zh) | 2018-10-23 |
| US20200347072A1 (en) | 2020-11-05 |
| US11453677B2 (en) | 2022-09-27 |
| EP3426656A1 (en) | 2019-01-16 |
| US20190092780A1 (en) | 2019-03-28 |
| EP3426656B1 (en) | 2021-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6918819B2 (ja) | オルトミクソウイルス感染の処置に有用な三環式化合物 | |
| US10723725B2 (en) | Aminopyridine derivatives as TAM family kinase inhibitors | |
| CN113683614B (zh) | 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物 | |
| US8729271B2 (en) | Glycine transporter inhibiting substances | |
| US12071441B2 (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| US20260053834A1 (en) | Covalent modifiers of akt1 and uses thereof | |
| HK40033744A (en) | Compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| HK40033744B (zh) | 作为正粘病毒复制抑制剂用於治疗流感的化合物 | |
| HK40009791B (zh) | 用於治疗正粘病毒感染的稠合三环哒嗪酮化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210528 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210622 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210721 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6918819 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |